Nuvalent reports Q4 and FY2025 net loss; zidesamtinib PDUFA set for Sept 18, 2026

Nuvalent, Inc.

2025-FY EPS reported -$5.85

Net loss of $118.7M in Q4 2025 and $425.4M for full year 2025.
Cash, equivalents and marketable securities of $1.4B, runway into 2029.
FDA accepted zidesamtinib NDA; PDUFA target action date September 18, 2026.
NDA submission for neladalkib in ALK+ NSCLC planned first half 2026.
Closed $500M public offering of common stock in November 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.